文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

解读 EORTC QLQ-C30 和 EORTC QLQ-LC13 患者自身变化。

Interpreting Within-Patient Changes on the EORTC QLQ-C30 and EORTC QLQ-LC13.

机构信息

Outcometrix, Salida, CO, USA.

Merck Healthcare KGaA, Darmstadt, Germany.

出版信息

Patient. 2022 Nov;15(6):691-702. doi: 10.1007/s40271-022-00584-w. Epub 2022 Jun 30.


DOI:10.1007/s40271-022-00584-w
PMID:35771392
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9585005/
Abstract

INTRODUCTION: When determining if changes on patient-reported outcome (PRO) scores in clinical trials convey a meaningful treatment benefit, statistical significance tests alone may not communicate the patient perspective. Appraising within-patient changes on PRO scores against established thresholds can determine if improvements or deteriorations experienced by individuals are meaningful. To evaluate the appropriateness of thresholds for interpreting meaningful improvements and deterioration within individuals on the European Organisation for Research and Treatment of Cancer (EORTC) 30-item core instrument (QLQ-C30) and 13-item lung cancer module (QLQ-LC13), a series of psychometric methods were applied to data from a phase III randomized controlled clinical trial in non-small cell lung cancer. METHODS: Anchor-based methods of empirical cumulative distribution functions and classification statistics were employed using change scores from Baseline to Week 7 using changes on the QLQ-C30 Global Health Status item as an anchor. Distribution-based methods of one-half standard deviation and standard error of measurement identified the minimum amount of change each domain score can reliably measure. RESULTS: While the correlations between the domain scores and the anchor item were modest in size (i.e., r ≥ 0.30 for only 5 of 24 domains), consideration of multiple methods along with the magnitude of possible step changes on the score allowed for patterns to emerge. The triangulation process planned a priori resulted in different methods being the source for different domain scores. Absolute values of the proposed thresholds ranged from 11.11 to 33.33, and all resulted in the same classifications for all EORTC domains, except QLQ-C30 Fatigue, as would the 10-point threshold that is traditionally used. CONCLUSION: This study confirms the appropriateness of the 10-point EORTC score threshold generally used by the field for interpreting within-patient changes, but the thresholds proposed from this study enhance interpretability by corresponding to only observable locations along the domain score scale.

摘要

简介:在临床试验中,当确定患者报告结局(PRO)评分的变化是否具有有意义的治疗益处时,仅进行统计学显著性检验可能无法传达患者的观点。评估 PRO 评分的个体内变化是否超过既定阈值,可以确定个体经历的改善或恶化是否具有意义。为了评估欧洲癌症研究与治疗组织(EORTC)30 项核心量表(QLQ-C30)和 13 项肺癌模块(QLQ-LC13)用于解释个体内有意义的改善和恶化的阈值是否合适,采用了一系列心理测量方法,对非小细胞肺癌 III 期随机对照临床试验的数据进行了分析。

方法:使用基于分布的方法,即基于基线至第 7 周的变化分数,使用 QLQ-C30 全球健康状况项目的变化作为锚点,采用经验累积分布函数和分类统计的基于锚点的方法。基于分布的方法使用一半标准差和测量误差标准确定每个域分数可以可靠测量的最小变化量。

结果:虽然域分数与锚定项目之间的相关性较小(即,只有 24 个域中的 5 个域的 r 值≥0.30),但考虑多种方法以及分数上可能发生的阶跃变化的幅度,可以发现一些模式。预先计划的三角剖分过程导致不同的方法成为不同域分数的来源。所提出的阈值的绝对值范围为 11.11 到 33.33,除了 QLQ-C30 疲劳量表外,所有这些阈值都与传统使用的 10 分阈值一样,适用于所有 EORTC 域的分类。

结论:这项研究证实了该领域通常用于解释个体内变化的 10 分 EORTC 评分阈值的适当性,但本研究提出的阈值通过与域评分尺度上仅可观察到的位置相对应,提高了可解释性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f78/9585005/781fb5153dbd/40271_2022_584_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f78/9585005/67504ad94ec9/40271_2022_584_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f78/9585005/6c0a4ff45c9a/40271_2022_584_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f78/9585005/781fb5153dbd/40271_2022_584_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f78/9585005/67504ad94ec9/40271_2022_584_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f78/9585005/6c0a4ff45c9a/40271_2022_584_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f78/9585005/781fb5153dbd/40271_2022_584_Fig3_HTML.jpg

相似文献

[1]
Interpreting Within-Patient Changes on the EORTC QLQ-C30 and EORTC QLQ-LC13.

Patient. 2022-11

[2]
Establishing Meaningful Change Thresholds in Patient-Reported Outcomes Among Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in ALTA-1L Trial.

Value Health. 2024-2

[3]
The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life.

Eur J Cancer. 1994

[4]
Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.

Gynecol Oncol. 2020-11

[5]
Estimating the minimally important difference for the EQ-5D-5L and EORTC QLQ-C30 in cancer.

Health Qual Life Outcomes. 2024-9-20

[6]
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.

Lung Cancer. 2020-6

[7]
Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types.

Eur J Cancer. 2023-7

[8]
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.

Lancet Oncol. 2017-8

[9]
Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study.

Lancet Oncol. 2020-3-23

[10]
Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma.

Eur J Cancer. 2018-10-22

引用本文的文献

[1]
Longitudinal graphics of patient-reported physical function in patients treated for hematologic malignancies.

BMC Med Res Methodol. 2025-8-7

[2]
FURLONG study: reply on the patient reported outcome measures and thresholds.

Lancet Reg Health West Pac. 2025-3-10

[3]
Recovery of quality of life in 574 patients with inoperable lung cancer undergoing (chemo)radiotherapy.

Clin Transl Radiat Oncol. 2025-2-22

[4]
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.

J Clin Oncol. 2025-5

[5]
Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®).

Qual Life Res. 2025-2

[6]
Effects of Symptom Burden on Quality of Life in Patients with Lung Cancer.

Curr Oncol. 2024-10-12

[7]
Optimizing lung cancer surgery in the elderly: sublobar resection versus lobectomy for early-stage non-small cell lung cancer patients aged 80 and above.

Discov Oncol. 2024-10-23

[8]
Safety and Preliminary Efficacy of Once-Weekly Split-Dose Selinexor in Soft Tissue Sarcoma: Results of the Phase Ib METSSAR Clinical Trial.

Target Oncol. 2024-9

[9]
Repotrectinib in Fusion-Positive Non-Small-Cell Lung Cancer.

N Engl J Med. 2024-1-11

本文引用的文献

[1]
Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials.

Lung Cancer. 2022-5

[2]
US Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January, 2008, and December, 2017.

Lancet Oncol. 2019-9-30

[3]
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.

J Thorac Oncol. 2019-1-31

[4]
Learning from Patients: Reflections on Use of Patient-Reported Outcomes in Lung Cancer Trials.

J Thorac Oncol. 2018-12

[5]
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.

Lancet Oncol. 2018-9-24

[6]
Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores.

Qual Life Res. 2017-6-15

[7]
A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research.

J Chiropr Med. 2016-6

[8]
Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms.

Clin Cancer Res. 2016-1-12

[9]
Minimal important differences in the EORTC QLQ-C30 in patients with advanced cancer.

Asia Pac J Clin Oncol. 2014-6

[10]
Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials.

Support Care Cancer. 2010-10-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索